Aclarion Delays CLARITY Readout, Broadens Enrollment Criteria to Speed Trial
ACON sits 21% above its 52-week low of $1.95 on light trading volume (0.2× avg).
Summary
Aclarion is revising enrollment criteria for its pivotal CLARITY trial after operational efforts failed to hit the pace needed for a Q4 2026 initial readout. The company will now provide an enrollment update and anticipated readout timeline by year-end, effectively pushing the readout beyond the prior quarter. Revised inclusion/exclusion criteria have been approved by IRBs at 9 of 11 active sites, with the remaining two using the new criteria for screening pending local approval. Management expects the broader criteria to accelerate enrollment and keep the overall trial duration on track, but the delay signals slower-than-expected progress on the company's key clinical catalyst. This follows a Q2 2026 loss of $2.75M and a $10.4M capital raise that extended cash runway into H2 2027, with insider buying in August showing management confidence. The year-end update will be the next concrete milestone for investors to assess whether the revised criteria actually deliver the promised acceleration.
At the time of this announcement, ACON was trading at $2.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $1.95 to $12.03. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.